-
公开(公告)号：US20160143965A1
公开(公告)日：2016-05-26
申请号：US14787581
申请日：2014-04-30
Applicant: FERRING B.V. , INSTITUT PASTEUR
Inventor： Pascal Danglas , Laurent Debarbieux
Abstract: The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject. The subject invention also provides new bacteriophage strains.
Abstract translation: 本发明提供了一种药物组合物，其包含：（i）能够在粘附侵入性大肠杆菌菌株中产生裂解感染的至少一种噬菌体菌株; 和（ii）药学上可接受的载体; 用于治疗炎性肠病。 本发明进一步提供了一种治疗炎症性肠病的方法，包括向有需要的受试者施用能够在粘附侵入性大肠杆菌菌株中产生裂解感染的至少一种噬菌体菌株，从而治疗受试者。 本发明还提供了新的噬菌体菌株。
-
公开(公告)号：US20240342230A1
公开(公告)日：2024-10-17
申请号：US18427221
申请日：2024-01-30
Applicant: FERRING B.V. , INSTITUT PASTEUR
Inventor： Pascal Danglas , Laurent Debarbieux
CPC classification number: A61K35/76 , A61K9/0053 , C12N7/00 , C12N2795/10021 , C12N2795/10132 , C12N2795/10171 , Y02A50/30
Abstract: The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease.
The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject.
The subject invention also provides new bacteriophage strains.
-
公开(公告)号：US20210386805A1
公开(公告)日：2021-12-16
申请号：US17353337
申请日：2021-06-21
Applicant: FERRING B.V. , INSTITUT PASTEUR
Inventor： Pascal Danglas , Laurent Debarbieux
Abstract: The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject. The subject invention also provides new bacteriophage strains.
-
公开(公告)号：US11918613B2
公开(公告)日：2024-03-05
申请号：US17353337
申请日：2021-06-21
Applicant: FERRING B.V. , INSTITUT PASTEUR
Inventor： Pascal Danglas , Laurent Debarbieux
CPC classification number: A61K35/76 , A61K9/0053 , C12N7/00 , C12N2795/10021 , C12N2795/10132 , C12N2795/10171 , Y02A50/30
Abstract: The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject. The subject invention also provides new bacteriophage strains.
-
公开(公告)号：US11040078B2
公开(公告)日：2021-06-22
申请号：US14787581
申请日：2014-04-30
Applicant: FERRING B.V. , INSTITUT PASTEUR
Inventor： Pascal Danglas , Laurent Debarbieux
Abstract: The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject. The subject invention also provides new bacteriophage strains.
-
公开(公告)号：US10441627B2
公开(公告)日：2019-10-15
申请号：US15510781
申请日：2015-09-14
Applicant: Ferring B.V.
Inventor： Pascal Danglas , Michael Reidy , Paul Korner , Sudarkodi Alagarsamy
Abstract: This disclosure relates to a method of treating Prader-Willi Syndrome. The method includes administering to a patient in need thereof an effective amount of a composition containing a selective oxytocin receptor agonist or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20170326200A1
公开(公告)日：2017-11-16
申请号：US15510781
申请日：2015-09-14
Applicant: Ferring B.V.
Inventor： Pascal Danglas , Michael Reidy , Paul Korner , Sudarkodi Alagarsamy
CPC classification number: A61K38/095 , A61K9/0043 , A61K9/08 , A61K47/02
Abstract: This disclosure relates to a method of treating Prader-Willi Syndrome. The method includes administering to a patient in need thereof an effective amount of a composition containing a selective oxytocin receptor agonist or a pharmaceutically acceptable salt thereof.
